Use of levodopa decarbozylase inhibitor

PheWeb

PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Medicine purchases: ATC N04BA02

3440

Check pre-conditions, main-only, mode, ICD version None

2673

Check minimum number of events

Min. number of events 3

2673

Include endpoints None

2673

PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

Extra metadata

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Use of levodopa decarbozylase inhibitor based on the number of shared cases.

Broader endpoints:

Any prescribed medicine buy

Narrower endpoints:

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	2599	1083	1516
Unadjusted prevalence (%)	0.84	0.62	1.12
Mean age at first event (years)	68.85	67.84	69.57

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.05	3.92 [3.21, 4.77]	9.8e-42	766
15 years	0.01	2.17 [1.79, 2.63]	2.7e-15	397
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR – Use of levodopa decarbozylase inhibitor
GWS hits:

Survival analyses between endpoints

↥

Plot

before Use of levodopa decarbozylase inhibitor
after Use of levodopa decarbozylase inhibitor

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Use of levodopa decarbozylase inhibitor

↥